IN THE CLAIMS:

1. **(Original)** An amorphous compound of 2-(1-isopropoxy-carbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine having no diffraction peak in a powder X-ray diffraction pattern and a solubility of 15 to 20 μg/mL in a 1 wt % methylcellulose solution at 37°C.

2. **(Original)** A composition comprising the amorphous compound according to claim 1 and methylcellulose and/or hydroxypropylmethylcellulose.

3. **(Previously presented)** The composition according to claim 2, wherein the mixing ratio of the amorphous compound of 2-(1-isopropoxy-carbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine to the total amount of methylcellulose and/or hydroxypropylmethylcellulose is in the range of 1:0.01 to 2.

4. **(Cancelled)**.

5. **(Previously presented)** A composition comprising the amorphous compound according to claim 1 and a polymer compound, wherein the polymer compound is one or at least two compounds selected from the group consisting of ethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylcellulose, carboxymethylethylcellulose, polyvinyl pyrrolidone, polyvinyl acetal diethylaminoacetate, methacrylic acid copolymer L, aminoalkyl methacryl acrylate copolymer E, and vinyl acetate-vinylpyrrolidone copolymer.

6. **(Original)** A process for producing the amorphous compound according to claim 1, said process comprising the steps of: dissolving 2-(1-isopropoxycarbonyloxy -2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c]- [1]benzazepine in methylene chloride to prepare a solution; and then spray-drying the solution.

7. **(Previously presented)** A process for producing the composition according to claim 2 , said process comprising the steps of: dissolving 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine and methylcellulose and/or hydroxypropylmethylcellulose in methylene chloride to prepare a solution; and then spray-drying the solution.

8. **(Previously presented)** A process for producing the composition according to claim 5, said process comprising the steps of: dissolving 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine and the polymer compound in methylene chloride or a methylene chloride/lower alcohol mixed solvent to prepare a solution; and then spray-drying the solution.

9. **(Original)** The process according to claim 8, wherein the lower alcohol is an alkyl alcohol having 1 to 3 carbon atoms.

10. **(Previously presented)** A pharmaceutical composition for oral administration, comprising the amorphous compound according to claim 1 and a pharmaceutically acceptable carrier.

11. **(Cancelled)**.

12. **(Previously presented)** A method for treating an allergic disease, wherein said method comprising the step of administering the amorphous compound according to claim 1 to an animal including a human.

13. **(Cancelled)**.

14. **(Previously presented)** A pharmaceutical composition for oral administration, comprising the composition according to claim 2 and a pharmaceutically acceptable carrier.

15. **(Previously presented)** A pharmaceutical composition for oral administration, comprising the composition according to claim 3 and a pharmaceutically acceptable carrier.

16. **(Previously presented)** A pharmaceutical composition for oral administration, comprising the composition according to claim 5 and a pharmaceutically acceptable carrier.

17. **(Previously presented)** A method for treating an allergic disease, wherein said method comprising the step of administering the composition according to claim 2 to an animal including a human.

18. **(Previously presented)** A method for treating an allergic disease, wherein said method comprising the step of administering the composition according to claim 3 to an animal including a human.

19. **(Previously presented)** A method for treating an allergic disease, wherein said method comprising the step of administering the composition according to claim 5 to an animal including a human.